Our Team - Attogene

Here at Attogene our team is focused on enhancing global health and the environment by offering and developing customer focused Life Science products.

Lance P. Ford, PhD.

President and CEO of Attogene Corporation

Dr. Ford, the CEO and President of Attogene Corporation, graduated in 1994 with his Bachelor of Science Degree from Montclair State University with a major in Molecular Biology. Dr. Ford subsequently attended Rutgers Robert Wood Johnson Medical School and graduated from the department of Microbiology and Molecular Genetics with his PhD in 1998. After completing his PhD, he obtained his postdoctoral fellowship at University of Texas Southwestern Medical Center in Dallas Texas in the Department of Cell Biology. Dr. Ford was an experienced officer of a successful biotechnology company, Bioo Scientific, where he was involved in many high-level corporate decisions including the ultimate sale of the company to Perkin Elmer and integration of Bioo Scientific into the larger organization. In 2018 after which he began operations of Attogene to focus on developing and commercializing revolutionary scientific technology and to grow a sustainable, thriving, cutting edge business in Austin Texas.

Joseph Krebs, PhD

Technology Officer

Dr. Krebs has worked in the commercial Biotechnology industry for more than 25 years. During that time, he has worked on a wide range of technologies and market areas including Pharmaceuticals, Plastics/Bioremediation, Life Science reagents, Food Safety, and Diagnostics. Joe received his Ph.D. in Biochemistry at Duke University and performed post-doctoral research at the Scripps Research Institute in Enzyme Structure and Mechanism. Joe’s focus at Attogene includes protein and antibody production as well as development of diagnostic assays.

Brian But, B.S.

Laboratory Technical Leader

Vast knowledge of ELISA, Lateral Flow and Enzyme assay technology with over 10 years of experience in the Biomanufacturing industry. In addition, Brian has strategic skills in assay development, materials management, inventory, quality control, and batch scale up with high precision and accuracy under ISO9001 guidelines. He has developed and tested complex kits and optimized corresponding standards; antibodies; HRPs; extraction buffers. Brian manages the operations team to maximize potential and efficiency by training new employees in work processes, internal operation standards and chemical safety. He also organizes weekly production meetings to determine future manufacturing plans, arranged group work for the team.

ADVISORS

Jeff Wilusz, PhD

Chief Scientific Advisor

Dr. Wilusz is a Professor at Colorado State University in the Department of Microbiology, Immunology and Pathology since 2003, and is associated with the University’s world recognized Center for Vector-Borne Infectious Diseases Laboratories. He has significant experience in developing new technologies and approaches for controlling and understanding the detection, treatment, and regulation of insect borne diseases. He has authored over 100 peer-reviewed publications and is an elected Fellow of the AAAS.

Jason Cook, PhD

Engineering Advisor

Jason has over 15 years of experience in the development and commercialization of diagnostics. Jason is currently the Chief Technology Officer of Bluejay Diagnostics (Nasdaq BJDX), where he leads product development of in-vitro diagnostics undergoing FDA clearance. Jason is also currently the Chief Executive Officer of NanoHybrids, Inc., a biotech company specializing in nanoparticle agents for the diagnosis and treatment of disease. Jason also has authored numerous journal papers, patents, and serves as a scientific reviewer for the National Institutes of Health on numerous panels.

Emanuel Labourier, PhD

Strategy Advisor

Dr. Labourier is an in vitro diagnostics executive with 20+ years of product development experience in the life sciences, molecular diagnostics, and clinical laboratory industries. He has extensive expertise in the development, validation, and commercialization of molecular tests, combined with a broad experience in technology management, startup strategy, and corporate consulting. Dr. Labourier has a proven track record of innovation, scientific leadership, and intellectual property development. He is an author or co-author of over 70 peer-reviewed publications and patent applications.